Home > Insider Trading > Filing (0001127602-15-019787)

Filing Details

Accession Number:: 0001127602-15-019787
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-03 19:16:06
Reporting Period:: 2015-06-02

Filing Date:: 2015-06-03
Accepted Time:: 2015-06-03 19:16:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1560565	M Cynthia Patton	One Amgen Center Drive Thousand Oaks CA 91320-1799	Svp & Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-06-02	4,530	$157.06	16,571	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	237	Indirect	401(k) Plan

Footnotes

The price reported is an average price. The prices ranged from $154.80 to $157.97 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 408 RSUs which vest on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 282 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.